PRVL News and Press, Prevail Therapeutics Inc. From 11/18/19

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of Morgan Sheng, Ph.D., to its Board ...

Prevail Therapeutics (NASDAQ: PRVL ): Q3 GAAP EPS of -$0.62 misses by $0.11 . More news on: Prevail Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations PR001 for Neuronopathic Gaucher Disease and PR006 for Frontotemporal Dementia with GRN Mutations Progressing Towards Clinic Ongoing Collaboration with Lonza to Sup...

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today annou...

Prevail Therapeutics (NASDAQ: PRVL ) has entered into a strategic collaboration with Lonza, an integrated solutions provider that creates value along the Healthcare Continuum. More news on: Prevail Therapeutics Inc., Healthcare stocks news, Read more ...

Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases Companies to partner on process development, analytical development, and large-scale manufacturing for lat...

Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...

NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today annou...

Gainers:  Emmaus Life Sciences ( OTC:EMMA ) +64% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +23% . SYNNEX Corporation (NYSE: SNX ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +17% . R.R. Donnelley & Sons Company (NYSE: RRD ) +16% . Comtech Telecommunications (NASDAQ...

Introduction In Q2/2019, Regenxbio Inc. ( RGNX ), achieved its first commercial-stage success with FDA approval of Zolgensma , a gene therapy infusion therapy for pediatric patients with spinal muscular atrophy ((SMA)), a leading genetic cause of infant mortality. RGNX is a small-cap ($...